Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: FTC Solar Q1 Earnings

FTC Solar (NASDAQ:FTCI) reported its Q1 earnings results on Wednesday, May 10, 2023 at 06:30 AM. Here’s what…
byBenzinga Insights
May 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

FTC Solar (NASDAQ:FTCI) reported its Q1 earnings results on Wednesday, May 10, 2023 at 06:30 AM.

Here’s what investors need to know about the announcement.

Earnings

FTC Solar beat estimated earnings by 22.22%, reporting an EPS of $-0.07 versus an estimate of $-0.09.

Revenue was down $8.66 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0 which was followed by a 5.86% drop in the share price the next day.

Here’s a look at FTC Solar’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.11 -0.18 -0.16 -0.12
EPS Actual -0.11 -0.17 -0.18 -0.20
Revenue Estimate 30.38M 17.22M 32.39M 61.75M
Revenue Actual 26.22M 16.57M 30.72M 49.55M

To track all earnings releases for FTC Solar visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

By Jelena Martinovic
March 27, 6:32 PM
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF